Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Oxyntomodulin (OXM) is a glucagon-like peptide 1 (GLP-1) receptor (GLP1R)/glucagon receptor (GCGR) dual agonist peptide that reduces body weight in obese subjects through increased energy expenditure and decreased energy intake. The metabolic effects of OXM have been attributed primarily to GLP1R agonism. We examined whether a long acting GLP1R/GCGR dual agonist peptide exerts metabolic effects in diet-induced obese mice that are distinct from those obtained with a GLP1R-selective agonist. RESEARCH DESIGN AND METHODS: We developed a protease-resistant dual GLP1R/GCGR agonist, DualAG, and a corresponding GLP1R-selective agonist, GLPAG, matched for GLP1R agonist potency and pharmacokinetics. The metabolic effects of these two peptides with respect to weight loss, caloric reduction, glucose control, and lipid lowering, were compared upon chronic dosing in diet-induced obese (DIO) mice. Acute studies in DIO mice revealed metabolic pathways that were modulated independent of weight loss. Studies in Glp1r−/− and Gcgr−/− mice enabled delineation of the contribution of GLP1R versus GCGR activation to the pharmacology of DualAG. RESULTS: Peptide DualAG exhibits superior weight loss, lipid-lowering activity, and antihyperglycemic efficacy comparable to GLPAG. Improvements in plasma metabolic parameters including insulin, leptin, and adiponectin were more pronounced upon chronic treatment with DualAG than with GLPAG. Dual receptor agonism also increased fatty acid oxidation and reduced hepatic steatosis in DIO mice. The antiobesity effects of DualAG require activation of both GLP1R and GCGR. CONCLUSIONS: Sustained GLP1R/GCGR dual agonism reverses obesity in DIO mice and is a novel therapeutic approach to the treatment of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data showed that with weekly administration, it normalized glucose tolerance and led to weight loss by the reduction of food intake and increased energy expenditure in obese mice [41].”
From The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. (2024) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with preclinical and early-phase clinical trials supporting their potential as next-generation obesity treatments [16–23].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dual and triple agonists have been shown to promote greater body weight loss and reduce food intake in obesity animal models than GLP-1 RAs alone [17,155,156,157,158].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [155]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first monomolecular glucagon receptor/GLP-1 receptor co-agonist was discovered in 2009, and its weekly administration significantly improved carbohydrate metabolism and reduced weight in obese mice fed a high-calorie diet during preclinical studies [97].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [97]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“protection from obesity is also observed in Glp1r-deficient mice114,115”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [114]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Self-citationSubcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372
Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363
Langin, D. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.03.009 · Cited by 359
Ørskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325
Oxyntomodulin Inhibits Food Intake in the Rat
Dakin, C. L., Gunn, I., Small, C. J., Edwards, C. M. B., Hay, D. L., Smith, D. M., Ghatei, M. A., & Bloom, S. R. (2001) · Endocrinology · doi:10.1210/endo.142.10.8430 · Cited by 281
The Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting
Longuet, C., Sinclair, E. M., Maida, A., Baggio, L. L., Maziarz, M., Charron, M. J., & Drucker, D. J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.008 · Cited by 272
Holst, J. J. (1997) · Annual Review of Physiology · doi:10.1146/annurev.physiol.59.1.257 · Cited by 267
Jocken, J. W. E., Langin, D., Smit, E., Saris, W. H. M., Valle, C., Hul, G. B., Holm, C., Arner, P., & Blaak, E. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1318 · Cited by 264
Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase–1
Jiang, G., Li, Z., Liu, F., Ellsworth, K. P., Dallas-Yang, Q., Wu, M. S., Ronan, J., Esau, C., Murphy, C., Szalkowski, D., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23962 · Cited by 255
Self-citationPrevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase–1
Jiang, G., Li, Z., Liu, F., Ellsworth, K., Dallas-Yang, Q., Wu, M., Ronan, J., Esau, C., Murphy, C., Szalkowski, D., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523962 · Cited by 241
Self-citationBiologic actions and therapeutic potential of the proglucagon-derived peptides
Drucker, D. J. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0017 · Cited by 230
The Role of Dipeptidyl Peptidase IV in the Cleavage of Glucagon Family Peptides
Zhu, L., Tamvakopoulos, C., Xie, D., Dragovic, J., Shen, X., Fenyk-Melody, J. E., Schmidt, K., Bagchi, A., Griffin, P. R., Thornberry, N. A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212355200 · Cited by 221
Self-citationSloop, K. W., Cao, J. X.-C., Siesky, A. M., Zhang, H. Y., Bodenmiller, D. M., Cox, A. L., Jacobs, S. J., Moyers, J. S., Owens, R. A., Showalter, A. D., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420911 · Cited by 219
Petersen, K. F., & Sullivan, J. T. (2001) · Diabetologia · doi:10.1007/s001250100006 · Cited by 209
Liang, Y., Osborne, M. C., Monia, B. P., Bhanot, S., Gaarde, W. A., Reed, C., She, P., Jetton, T. L., & Demarest, K. T. (2004) · Diabetes · doi:10.2337/diabetes.53.2.410 · Cited by 202
Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII
LEITING, B., PRYOR, K. D., WU, J. K., MARSILIO, F., PATEL, R. A., CRAIK, C. S., ELLMAN, J. A., CUMMINGS, R. T., & THORNBERRY, N. A. (2003) · Biochemical Journal · doi:10.1042/bj20021643 · Cited by 181
Self-citationEffect of Glucagon on Food Intake and Body Weight in Man
Schulman, J. L., Carleton, J. L., Whitney, G., & Whitehorn, J. C. (1957) · Journal of Applied Physiology · doi:10.1152/jappl.1957.11.3.419 · Cited by 174
Stimulation of Feeding in Rats by Intraperitoneal Injection of Antibodies to Glucagon
Langhans, W., Zeiger, U., Scharrer, E., & Geary, N. (1982) · Science · doi:10.1126/science.7134979 · Cited by 149
Schjoldager, B., Baldissera, F. G. A., Mortensen, P. E., Holst, J. J., & Christiansen, J. (1988) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1988.tb01046.x · Cited by 134
Runge, S., Wulff, B. S., Madsen, K., Bräuner‐Osborne, H., & Knudsen, L. B. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705120 · Cited by 133
Depression of Food Intake Induced in Healthy Subjects by Glucagon
Penick, S. B., Hinkle, L. E., & Paulsen, E. G. (1961) · New England Journal of Medicine · doi:10.1056/nejm196105042641801 · Cited by 125
Dipeptidyl Peptidase IV (DPIV/CD26) Degradation of Glucagon
Hinke, S. A., Pospisilik, J. A., Demuth, H.-U., Manhart, S., Kühn‐Wache, K., Hoffmann, T., Nishimura, E., Pederson, R. A., & McIntosh, C. H. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.3827 · Cited by 123
Maida, A., Lovshin, J. A., Baggio, L. L., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2008-0336 · Cited by 122
Gros, L., Thorens, B., BATAILLE, D., & Kervran, A. (1993) · Endocrinology · doi:10.1210/endo.133.2.8102095 · Cited by 121
Baldissera, F. G. A., Holst, J. J., Knuhtsen, S., Hilsted, L., & Nielsen, O. V. (1988) · Regulatory Peptides · doi:10.1016/0167-0115(88)90099-7 · Cited by 114
A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects
Qureshi, S. A., Candelore, M. R., Xie, D., Yang, X., Tota, L. M., Ding, V. D. H., Li, Z., Bansal, A., Miller, C. O., Cohen, S. M., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.12.3267 · Cited by 112
Self-citationFibroblast Growth Factor-21 as a Therapeutic Agent for Metabolic Diseases
Kharitonenkov, A., & Shanafelt, A. B. (2008) · BioDrugs · doi:10.2165/00063030-200822010-00004 · Cited by 104
Metabolic effects of glucagon in the Wistar rat
SALTER, J. M. (1960) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/8.5.535 · Cited by 85 · cited 1×
“The hormone has been reported to decrease total cholesterol in rats and to cause a greater reduction in body weight compared with a pair-fed group of animals because of both reduced food intake and increased energy expenditure (19).”
BackgroundRunge, S., Gram, C., Bräuner‐Osborne, H., Madsen, K., Knudsen, L. B., & Wulff, B. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301085200 · Cited by 69
Winzell, M. S., Brand, C. L., Wierup, N., Sidelmann, U. G., Sundler, F., Nishimura, E., & Åhrén, B. (2007) · Diabetologia · doi:10.1007/s00125-007-0675-3 · Cited by 68
The Obesity Epidemic: Pharmacological Challenges
Bloom, S. R., Kuhajda, F. P., Laher, I., Pi-Sunyer, X., Ronnett, G. V., Tan, T., & Weigle, D. S. (2008) · Molecular Interventions · doi:10.1124/mi.8.2.6 · Cited by 59
Adipose tissue gene expression profiles in ob/ob mice treated with leptin
Zhang, W., Della‐Fera, M. A., Hartzell, D. L., Hausman, D. B., & Baile, C. A. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.04.021 · Cited by 59
Sowden, G. L., Drucker, D. J., Weinshenker, D., & Swoap, S. J. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00405.2006 · Cited by 58
Metabolic clearance rates of oxyntomodulin and glucagon in the rat: contribution of the kidney
Kervran, A., Dubrasquet, M., Blache, P., Martínez, J., & BATAILLE, D. (1990) · Regulatory Peptides · doi:10.1016/0167-0115(90)90194-2 · Cited by 53
Adipose Triglyceride Lipase Gene Expression in Human Visceral Obesity
Berndt, J., Kralisch, S., Klöting, N., Ruschke, K., Kern, M., Fasshauer, M., Schön, M., Stümvoll, M., & Blüher, M. (2007) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2007-993148 · Cited by 52
Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet
Parlevliet, E. T., Heijboer, A. C., der Elst, J. P. S.-V., Havekes, L. M., Romijn, J. A., Pijl, H., & Corssmit, E. P. M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00576.2007 · Cited by 49
Knop, F. K., Vilsbøll, T., Larsen, S., Madsbad, S., Holst, J. J., & Krarup, T. (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2581 · Cited by 44
Minkler, P. E., Kerner, J., Kasumov, T., Parland, W., & Hoppel, C. L. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.02.015 · Cited by 39
The role of glucagon in diabetes.
Unger, R. H., & Orci, L. (1982) · PubMed · Cited by 14
Karnieli, E. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.07.005 · Cited by 4
[Role of glucagon in diabetes].
Lefèbvre, P., & LUYCKX, A. S. (1981) · PubMed · Cited by 3
Ezzat, S., & Asa, S. L. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.03.002 · Cited by 2
Cited by
Peptide therapeutics: current status and future directions
Fosgerau, K., & Hoffmann, T. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,030
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
“In fat-fed rodents, a long-acting dual GLP1R/ GCGR agonist resulted in greater weight loss than a pure GLP1R agonist, with improvements in hepatic steatosis and changes in gene expression consistent with increased hepatic lipid oxidation (Pocai et al., 2009).”
Enteroendocrine Cells: Chemosensors in the Intestinal Epithelium
Gribble, F. M., & Reimann, F. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105439 · Cited by 683
Metadata
- Authors
- Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., Liu, F., Miller, C., Tota, L. M., Zhou, G., Zhang, X., Sountis, M. M., Santoprete, A., Capito', E., Chicchi, G. G., Thornberry, N., Bianchi, E., Pessi, A., Marsh, D. J., & SinhaRoy, R.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Istituto di Ricerche di Biologia Molecolare P. Angeletti, Pomezia, Rome, Italy.
- Corresponding author
- Marsh, Donald J.
- SinhaRoy, Ranabir
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-07-14
- Volume
- 58
- Issue
- 10
- Pages
- 2258-2266
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2750209
- OpenAlex
- W2122188063
- Cited by
- 409
- References
- 47
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 32 · 2023: 25 · 2022: 18 · 2021: 25 · 2020: 30 · 2019: 28 · 2018: 38 · 2017: 25 · 2016: 29 · 2015: 28 · 2014: 20 · 2013: 29 · 2012: 24
- FWCI
- 8.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- glucagon-like peptide-1, glucagon receptor, oxyntomodulin, obesity, diet-induced obesity, weight loss, lipid lowering, hypoglycemic effect, fatty acid oxidation, hepatic steatosis, insulin, leptin, adiponectin
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Amino Acid Sequence, Animals, Body Weight, Energy Intake, Cricetulus, Diabetes Mellitus, Type 2, Dietary Fats, Cricetinae, Injections, Subcutaneous, Insulin, Mice, Inbred C57BL, Molecular Sequence Data, Obesity, Weight Loss, CHO Cells, Receptors, Glucagon, Reverse Transcriptase Polymerase Chain Reaction, Mice, Glucagon-Like Peptide 1, Oxyntomodulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.